New drug combo shows promise in slowing rare sarcoma growth
NCT ID NCT04807816
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the drug berzosertib to standard chemotherapy (gemcitabine) can help control a rare soft-tissue cancer called leiomyosarcoma. 58 adults with advanced or spreading disease took part. The goal was to see if the combination could stop or shrink tumors for at least 6 months. This is a disease-control approach, not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Poitiers
Poitiers, 86000, France
-
Centre Leon Berard
Lyon, 69008, France
-
IUCT Oncopôle
Toulouse, 31059, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Gustave Roussy
Villejuif, 94805, France